Therefore, L-selectin enhanced T cells respond to the presence of a tumor differently to L-selectin knockout T cells and upregulate CD69 both inside the tumor and at sites of antigen presentation and priming in secondary lymphoid organs. Here, CD69 is linked to neoplasm.